Lab21 Expands Companion Diagnostic Cancer Testing Service Internationally
News Jul 18, 2008
Lab21 now offer its newly launched K-RAS gene mutation and its epidermal growth factor receptor (EGFR) mutation testing services to its international customers.
The Company has seen the demand for K-RAS testing increase 10 fold since its launch at the beginning of the year and, with recent investment in people and systems, Lab21 is set to ramp capacity by 10 fold again to cope with the projected demand.
Recent drug licences for Vectibix™ and Erbitux™ require analysis of the KRAS gene in the tumor to assess if a patient will respond to the therapy. Through its international logistics function, Lab21 is now able to assist UK and international healthcare providers in screening patients for this genetic mutation.
Lab21’s fully accredited laboratories based in Cambridge, UK are already receiving patient samples from around the world including the Middle East, mainland Europe and the US. “Through our dedicated help-line, strong logistics and high quality testing function we are able to provide rapid turnaround from as little as 5-days and tailored reporting for many overseas customers”, added Dr Berwyn Clarke, CSDO of Lab21.
Dr Aladdin Maarraoui, Mafraq Hospital Abu Dhabi, commented “I am grateful to Lab21 for providing such quick and high quality results for my patients as testing for K-RAS mutation gives me great comfort that I will offer targeted therapy to the group of patients that are likely to respond to it. This is the future of oncology, to offer designer drugs for the group of patients who have the targeted mutated gene”.
A team of researchers has discovered a combination of pharmaceutical drugs that not only increases healthy lifespan in the microscopic worm Caenorhabditis elegans (C. elegans), but also delays the rate of ageing in them, a finding that could someday mean longer, healthier lives for humans.READ MORE
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
2nd AI Pharma Innovation: Drug Discovery 2019 Summit
Feb 27 - Feb 28, 2019
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019